Literature DB >> 16153121

Cleavage of disulfide-linked fetuin-bisphosphonate conjugates with three physiological thiols.

Sufeng Zhang1, Jennifer E I Wright, Geeti Bansal, Philip Cho, Hasan Uludag.   

Abstract

An effective therapeutic agent for treatment of bone diseases is expected to exhibit a high affinity to bone. Conjugating proteins to bisphosphonates (BPs), a class of molecules with an exceptional affinity to bone mineral hydroxyapatite (HA), is a feasible means to impart such a bone affinity. Protein-BP conjugates with cleavable linkages, which allow protein release from the mineral, are preferable over conjugates with stable linkages. To this end, 2-(3-mercaptopropylsulfanyl)-ethyl-1,1-bisphosphonic acid (thiolBP) was conjugated onto fetuin, a model protein, using N-succinimidyl-3-(2-pyridyldithio)propionate to create disulfide-linked conjugates. Although the fetuin-thiolBP conjugates were stable under aqueous conditions, the disulfide linkage was readily cleaved in the presence of the physiological thiols l-cysteine, dl-homocysteine, and l-glutathione. dl-Homocysteine exhibited the highest cleavage of the disulfide linkage among these thiols. The imparted bone affinity as a result of thiolBP conjugation, as assessed by HA binding in vitro, was eliminated upon cleavage of the disulfide linkage. The cleavage of the conjugates bound to HA was as effective as the conjugate cleavage in solution, and even more so at high concentrations of l-glutathione. In conclusion, disulfide-linked fetuin-thiolBP conjugates exhibited a high affinity to HA, which was readily lost upon cleavage with thiols found in physiological milieu.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16153121     DOI: 10.1021/bm050273s

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  4 in total

1.  Characterization of synthesized NANO-encapsulated drug for bone loss on hind limb suspension rat model by NMR and micro-CT.

Authors:  Qingwen Ni; Hong Dixon; Gloria Gutierrez; Long Bi; Yi-Xian Qin
Journal:  Adv Biosci Bioeng (N Y)       Date:  2014-06-14

2.  Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis.

Authors:  Tong Liu; Svetlana Romanova; Shuo Wang; Megan A Hyun; Chi Zhang; Samuel M Cohen; Rakesh K Singh; Tatiana K Bronich
Journal:  Mol Pharm       Date:  2019-06-14       Impact factor: 4.939

3.  Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe Efstathiadou; Ioannis Litsas; Marina Kita; Athanasios Panagiotou; Athanasios Papatheodorou; Georgios Arsos; Efstratios Moralidis; Georgios Barmpalios; Efthimia Zafeiriadou; Efthimia Triantafillidou; Eleni Makrigiannaki; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2009-10-21       Impact factor: 2.626

Review 4.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.